Colin Cahill

Healthcare Investor & Operator | Medtech, Biotech, Life Science Tools, & Human Performance | Ex-SF Giants, Venrock | Selected boards: Cionic, Shockwave, 10x Genomics, RefleXion

📍 San Francisco, California, United States🔄 Updated September 2026💼 7 investments📅 14 years investing🗓 Last invested Feb 2026
VC🌍 United StatesInvested this year
7
Total investments
1
Early stage
1
Mid stage
2
Late stage
14y
Years active

Portfolio

5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Feb 2026
Cionic is pioneering the future of movement through an advanced system that combines wearable neurotechnology, adaptive AI, and connected care. With the FDA-cleared Neural Sleeve 2 at its core, Cionic is setting a new standard for mobility care today and building toward a future where people can move further, faster, and fearlessly, across every limb and every condition.
Board Member
May 2015
Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotripsy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. Stay connected with us at www.ShockwaveMedical.com and on Twitter @ShockwaveIVL
Board Observer
Mar 2014
SCINTIX biology-guided radiotherapy now FDA cleared. SCINTIX™ therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
Board Observer
Sep 2013
Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.
Board Observer
Dec 2012
Experience · 11 entries
All (11)
Investments (7)
Founder (2)
Board (6)
2026
Board Member
Feb 2026
Cionic is pioneering the future of movement through an advanced system that combines wearable neurotechnology, adaptive AI, and connected care. With the FDA-cleared Neural Sleeve 2 at its core, Cionic is setting a new standard for mobility care today and building toward a future where people can move further, faster, and fearlessly, across every limb and every condition.
2015
Board Member
May 2015
Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotripsy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. Stay connected with us at www.ShockwaveMedical.com and on Twitter @ShockwaveIVL
2014
Board Observer
Mar 2014
SCINTIX biology-guided radiotherapy now FDA cleared. SCINTIX™ therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
2013
Board Observer
Sep 2013
Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.
Ariosa Diagnostics
Board Observer
Jan 2013
Show all 11 entries ↓
Investment activity
2012–2026 · 7 investments
2012220132201412015120261
Recent (last 2 years)Earlier